Results 161 to 170 of about 70,936 (237)

Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1)

open access: yesChemMedChem, Volume 21, Issue 5, 13 March 2026.
DM1 is an RNA gain‐of‐function disease caused by CTG repeat expansion, producing toxic r(CUG)exp RNA that sequesters MBNL1 and impairs splicing. This review covers the field of CUG and CTG ligands identified or rationally designed as DM1 drug candidates, highlighting their molecular design, RNA‐ or DNA‐binding modes, in vitro affinities and ...
Camille Richagneux, Anton Granzhan
wiley   +1 more source

Refining insights on type 2 diabetes and aortic valve replacement—reply to Liu et al.

open access: yes
Diabetic Medicine, Volume 43, Issue 4, April 2026.
Timothy M. E. Davis, Wendy A. Davis
wiley   +1 more source

Home - About - Disclaimer - Privacy